GSK plc (GSK) ORD GBP0.3125
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
GSK posts promising results from gonorrhoea treatment trial
17 April 2024 07:11
(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid...
-
GSK meningococcal vaccine accepted by US FDA for review
16 April 2024 09:17
(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).
-
GSK unveils promising results from endometrial cancer trial
18 March 2024 12:00
(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.
-
GSK reports more encouraging trial results for Blenrep
7 March 2024 07:21
(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with...
-
GSK's ViiV upbeat on ultra-long-acting HIV treatment study
5 March 2024 07:26
(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an...
-
GSK reaches settlement in another Zantac case
29 February 2024 07:22
(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.
-
GSK reports positive results from gonorrhoea treatment trial
26 February 2024 07:22
(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.
-
GSK's ViiV sees success in latest HIV treatment trial
21 February 2024 07:22
(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its...
-
Berenberg hikes target price on GSK
15 February 2024 11:02
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of...
-
London close: Stocks fall as US inflation tops expectations
13 February 2024 16:21
(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within...
-
London close: Stocks fall as US inflation tops expectations
13 February 2024 16:21
(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within...
-
Citi ups recommendation on GSK to 'buy'
13 February 2024 09:45
(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.
Company announcements Announcements
-
Director/PDMR Shareholding
19 April 2024 15:30
GSK
-
GSK announces additional EAGLE-1 results
17 April 2024 07:05
GSK
-
Results from long-term data relating to Shingrix
17 April 2024 07:00
GSK
-
Amendment - Director/PDMR Shareholding
16 April 2024 14:11
GSK
-
FDA accepts GSK meningitis vaccine candidate file
16 April 2024 07:00
GSK
-
Director/PDMR Shareholding
15 April 2024 15:30
GSK
-
Replacement - Total Voting Rights
4 April 2024 12:05
GSK
-
Total Voting Rights
2 April 2024 15:00
GSK
-
Director/PDMR Shareholding
26 March 2024 15:30
GSK
-
Notice of AGM
25 March 2024 13:00
GSK
-
Transfer of Treasury Shares
22 March 2024 16:20
GSK
-
Director/PDMR Shareholding
22 March 2024 15:36
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.